Cellectis Sub-Licenses Genomic Engineering IP to GlaxoSmithKline | GenomeWeb
NEW YORK (GenomeWeb News) — Cellectis has sub-licensed to GlaxoSmithKline patents for a process used to replace, remove, or insert genes in a genome by homologous recombination, Cellectis said Friday.
 
The company, which licensed the technology from the Pasteur Institute, said GlaxoSmithKline will use it in its drug research for in vitro and in vivo “modifications and manipulations of genetic material.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.